Design, preparation and characterization of novel poly-lactic-co-glycolic acid‑hyaluronic acid implants containing triptorelin acetate

Nersi Jafary Omid, Kourosh Toopchi, Niloofar Babanejad, Zeynab Ehsanfar, Farid Dorkoosh

Abstract


Hormones and their derivatives are widely used to treat different types of diseases such as prostate cancer which is
treated by agonists of gonadotropin‑releasing hormone. Triptoreline salts are the first therapeutics of this group
launched into the market in the form of microparticles (microspheres). Implants, as one of attractive injectable dosage
forms, have many advantages over multi‑particulate systems. Some of these advantages are dose adjustability, drug absorption improvement, constant release profile, etc. In this research, a new composite of poly‑lactic‑co‑glycolic acid and hyaluronic acid was designed and prepared in the form of implants containing triptorelin acetate for administration as an injection under the skin (subcutaneously) in arm or thigh area. The manufactured implants characterized by Fourier transform infrared spectroscopy, thermas gravimetric analysis, X‑ray diffraction and scanning electron microscopy to assess different aspects of structure and morphology. The drug release profile was assessed by high performance liquid chromatography. These
characterizations confirmed that the newly designed drug delivery has a good stability during manufacturing process. The
release pattern of the implant was also studied and revealed that the release of the model drug follows a zero‑order and
erosion mechanism. The compatibility between the components of the newly designed implants and the release profile of
the delivery system make it a promising device for drug delivery.

Full Text:

PDF

References


Shaw G, Oliver RT. Intermittent hormone therapy and its place in the

contemporary endocrine treatment of prostate cancer. Surg Oncol

;18:275‑82.

Zhou B, Sun Q, Cong R, Gu H, Tang N, Yang L, et al. Hormone replacement

therapy and ovarian cancer risk: A meta‑analysis. Gynecol Oncol

;108:641‑51.

Martin LJ, Minkin S, Boyd NF. Hormone therapy, mammographic density,

and breast cancer risk. Maturitas 2009;64:20‑6.

Staren ED, Omer S. Hormone replacement therapy in postmenopausal

women. Am J Surg 2004;188:136‑49.

Cutler WB, Genovese‑Stone E. Wellness in women after 40 years of age:

The role of sex hormones and pheromones. Dis Mon 1998;44:421‑546.

Murad MH, Elamin MB, Garcia MZ, Mullan RJ, Murad A, Erwin PJ,

et al. Hormonal therapy and sex reassignment: A systematic review

and meta‑analysis of quality of life and psychosocial outcomes. Clin

Endocrinol 2010;72:214‑31.

Handelsman DJ, Zajac JD. 11: Androgen deficiency and replacement

therapy in men. Med J Aust 2004;180:529‑35.

Bolar K, Hoffman AR, Maneatis T, Lippe B. Long‑term safety of

recombinant human growth hormone in turner syndrome. J Clin

Endocrinol Metab 2008;93:344‑51.

Akehurst RL, Barnett D, Berry SC, Bird S, Buxton M, Claxton K, et al.

Guidance on the use of human growth hormone (somatropin) in

children with growth failure. Technology Appraisal Guidance No. 42 National Institute for Clinical Excellence. 2002.

Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ Jr. Effects of

thyroxine as compared with thyroxine plus triiodothyronine in patients

with hypothyroidism. N Engl J Med 1999;340:424‑9.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer

statistics. CA Cancer J Clin 2011;61:69‑90.

Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M. An overview

on 5alpha‑reductase inhibitors. Steroids 2010;75:109‑53.

Kraus S, Naor Z, Seger R. Gonadotropin‑releasing hormone in apoptosis

of prostate cancer cells. Cancer Lett 2006;234:109‑23.

Giteau A, Venier‑Julienne MC, Aubert‑Pouessel A, Benoit JP. How to

achieve sustained and complete protein release from PLGA‑based

microparticles? Int J Pharm 2008;350:14‑26.

Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable

poly (lactic‑co‑glycolic acid) microparticles for injectable delivery of

vaccine antigens. Adv Drug Deliv Rev 2005;57:391‑410.

Powell EM, Sobarzo MR, Saltzman WM. Controlled release of nerve

growth factor from a polymeric implant. Brain Res 1990;515:309‑11.

Yasukawa T, Kimura H, Tabata Y, Ogura Y. Biodegradable scleral plugs

for vitreoretinal drug delivery. Adv Drug Deliv Rev 2001;52:25‑36.

Fournier E, Passirani C, Montero‑Menei CN, Benoit JP. Biocompatibility

of implantable synthetic polymeric drug carriers: Focus on brain

biocompatibility. Biomaterials 2003;24:3311‑31.

Nitsch MJ, Banakar UV. Implantable drug delivery. J Biomater Appl

;8:247‑84.

Shi Y, Li LC. Current advances in sustained‑release systems for parenteral

drug delivery. Expert Opin Drug Deliv 2005;2:1039‑58.

Iyer SS, Barr WH, Karnes HT. Profiling in vitro drug release from

subcutaneous implants: A review of current status and potential

implications on drug product development. Biopharm Drug Dispos

;27:157‑70.

Hetrick EM, Prichard HL, Klitzman B, Schoenfisch MH. Reduced foreign

body response at nitric oxide‑releasing subcutaneous implants.

Biomaterials 2007;28:4571‑80.

Ratner BD. Reducing capsular thickness and enhancing angiogenesis

around implant drug release systems. J Control Release 2002;78:211‑8.

McTaggart LE, Halbert GW. Assessment of polysaccharide gels as drug

delivery vehicles. Int J Pharm 1993;100:199‑206.

Coviello T, Matricardi P, Marianecci C, Alhaique F. Polysaccharide

hydrogels for modified release formulations. J Control Release

;119:5‑24.

Xu X, Jha AK, Duncan RL, Jia X. Heparin‑decorated, hyaluronic acid‑based

hydrogel particles for the controlled release of bone morphogenetic

protein‑2. Acta Biomater 2011;7:3050‑9.

Tammi R, Ågren UM, Tuhkanen AL, Tammi M. Hyaluronan metabolism

in skin. Prog Histochem Cytochem 1994;29:1‑81.

Trommer H, Wartewig S, Böttcher R, Pöppl A, Hoentsch J, Ozegowski JH,

et al. The effects of hyaluronan and its fragments on lipid models

exposed to UV irradiation. Int J Pharm 2003;254:223‑34.

Sadighi A, Ostad SN, Rezayat SM, Foroutan M, Faramarzi MA,

Dorkoosh FA. Mathematical modelling of the transport of

hydroxypropyl‑beta‑cyclodextrin inclusion complexes of ranitidine

hydrochloride and furosemide loaded chitosan nanoparticles across a

Caco‑2 cell monolayer. Int J Pharm 2012;422:479‑88.

Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release

from controlled drug delivery systems. Acta Pol Pharm 2010;67:217‑23.

Higuchi T, Connors KA, Phase‑solubility techniques. Adv Anal Chem

Instrum 1965;4:117‑22.

Korsmeyer RW, Gumy R, Doelker E, Buri P, Peppas NA. Mechanisms of solute

release from porous hydrophilic polymers. Int J Pharm 1983;15:25‑35.

Fredenberg S, Wahlgren M, Reslow M, Axelsson A. The mechanisms

of drug release in poly (lactic‑co‑glycolic acid)‑based drug delivery

systems‑‑a review. Int J Pharm 2011;415:34‑52.




DOI: http://dx.doi.org/10.22377/ajp.v8i1.317

Refbacks

  • There are currently no refbacks.